Reading the tape
NASDAQ: FLGT
Fulgent Genetics, Inc.
Healthcare · Medical - Diagnostics & Research
Market Cap
$451.86M
52w High
$31.04
52w Low
$13.46
P/E
-7.73
Volume
497.16K
Outstanding Shares
29.75M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -12.45%Revenue (TTM): 13.83%FCF (TTM): -545.09%P/E: 0th pct
What changed
The stock fell 12.45% over the last year. Revenue grew 13.83% over the trailing twelve months. Operating margin moved from -26.08% to -28.23%. Free cash flow declined 545.09% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/E, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at -28.23%. Free cash flow fell 545.09% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
CEOMing Hsieh
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees1,313
IPO dateSep 29, 2016
Valuation
Forward P/E—
EV/EBITDA-16.56
Enterprise value$758.79M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth9.34%
Gross margin40.56%▲7.24%vs FY2024
Operating margin-28.23%▼8.27%vs FY2024
ROE-5.44%▼44.40%vs FY2024
Analyst consensus
RatingBuy
Target price$36.00▲137.00%
6
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 1, 2026
Q2 FY26 · EPS est -$0.35 · Revenue est $68.09M
View